In the third quarter, Commerzbank Aktiengesellschaft FI trimmed its position in AbbVie Inc. by 30.5%, selling 39,586 shares and ending the period with 90,102 shares valued at approximately $20.9 million. This move contrasts with larger institutional activity during the same quarter, including Norges Bank’s inaugural acquisition valued near $4.29 billion and Laurel Wealth Advisors’ 18,384% position increase to over 5.7 million shares worth about $1.06 billion. Overall, institutional and hedge funds now control roughly 70.2% of AbbVie’s outstanding shares.

AbbVie reported third-quarter revenue of $15.78 billion, up 9.1% year-over-year, and non-GAAP earnings per share of $1.86, exceeding consensus estimates by $0.09. Return on equity stood at an extraordinary 3,216%, while net margin was 4.0%. Management reiterated full-year guidance of $3.32 to $3.36 in EPS for 2025, and analysts have adjusted their outlooks accordingly: Morgan Stanley raised its target to $269 with an overweight rating, Guggenheim boosted its objective to $242 and maintained a buy recommendation, while Citigroup trimmed its neutral price target to $235. The consensus from 23 analysts remains a Moderate Buy.

AbbVie declared a quarterly dividend of $1.73 per share, payable February 17 to holders of record as of January 16, marking a 5.5% increase from the previous payout of $1.64. This raises the annualized dividend to $6.92 and lifts the dividend payout ratio to 524%, underscoring the company’s commitment to returning capital despite a high payout multiple. The new yield approaches 3.2%, positioning AbbVie among the higher-yielding Dividend Kings group and supporting its appeal to income-focused investors.